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H IV
Emtricitabine-Tenofovir Concentrations and
Pre-Exposure Prophylaxis Efficacy in Men Who Have
Sex with Men
Peter L. Anderson,1 David V. Glidden,2 Albert Liu,3 Susan Buchbinder,2,3
Javier R. Lama,4,5 Juan Vicente Guanira,5 Vanessa McMahan,6 Lane R. Bushman,1
Martín Casapía,7 Orlando Montoya-Herrera,8 Valdilea G. Veloso,9 Kenneth H. Mayer,10,11
Suwat Chariyalertsak,12 Mauro Schechter,13 Linda-Gail Bekker,14 Esper Georges Kallás,15,16
Robert M. Grant,2,6* For the iPrEx Study Team
Drug concentrations associated with protection from HIV-1 acquisition have not been determined. We evaluated
drug concentrations among men who have sex with men in a substudy of the iPrEx trial (1). In this randomized
placebo-controlled trial, daily oral doses of emtricitabine/tenofovir disoproxil fumarate were used as pre-exposure
prophylaxis (PrEP) inmenwho have sex withmen. Drug was detected less frequently in blood plasma and in viable
cryopreserved peripheral blood mononuclear cells (PBMCs) in HIV-infected cases at the visit when HIV was first
discovered compared with controls at the matched time point of the study (8% versus 44%; P < 0.001) and in
the 90 days before that visit (11% versus 51%; P < 0.001). An intracellular concentration of the active form of
tenofovir, tenofovir-diphosphate (TFV-DP), of 16 fmol per million PBMCs was associated with a 90% reduction
in HIV acquisition relative to the placebo arm. Directly observed dosing in a separate study, the STRAND trial,
yielded TFV-DP concentrations that, when analyzed according to the iPrEx model, corresponded to an HIV-1 risk
reduction of 76% for two doses per week, 96% for four doses per week, and 99% for seven doses per week. Pro-
phylactic benefits were observed over a range of doses and drug concentrations, suggesting ways to optimize
PrEP regimens for this population.
INTRODUCTION
The JointUnitedNations ProgrammeonHIV/AIDS (UNAIDS) estimates
that there are 2.6 million new HIV-1 infections per year, despite wide-
spread awareness of themodes of transmission and theprotective benefits
of condomuse (2). Menwho have sex withmen carry a disproportionate
burden of infection on all continents (3). Pre-exposure prophylaxis
(PrEP) using the antiretroviral drugs emtricitabine (FTC) and tenofovir
disoproxil fumarate (TDF) is a recently proven strategy for preventing
HIV acquisition in men who have sex with men. TDF is a prodrug for
tenofovir, which is an analog of deoxyadenosine-monophosphate. These
drugs require phosphorylation in mononuclear cells to the pharmaco-
logically active triphosphate anabolites, called emtricitabine-triphosphate
(FTC-TP) and tenofovir-diphosphate (TFV-DP).
In the iPrEx trial, HIV-negative men at risk for HIV infection were
randomized to daily oral dosing with emtricitabine/tenofovir (TFV)
disoproxil fumarate (FTC/TDF) or placebo for PrEP. Randomization
to active drug decreased HIV-1 acquisition by 44% compared with pla-
cebo, with greater reductions in HIV-1 acquisition risk associated with
higher reported adherence and detectable drug in the blood (1).
In a predefined pharmacology substudy of the iPrEx trial, drug in
plasma or peripheral blood mononuclear cells (PBMCs) was detected
in 22 of 43 seronegative subjects (51%) versus 3 of 34HIV-infected sub-
jects from the active arm (9%) (P < 0.001) (1). Predicted efficacy in the
iPrEx trial increased from 44% to more than 90% when detectable
drug was accounted for. Thus, adherence to daily doses of FTC-TDF
was critical for PrEP efficacy in the iPrEx trial, and the same has been
found in other PrEP studies (4–7). However, the quantitative relation-
ship between drug concentration and level of adherence with PrEP ef-
ficacy has not been determined. The current study expands on the
predefined pharmacology substudy of the iPrEx trial and quantifies
the concentrations of drugs associated with protection from HIV-1 ac-
quisition, as well as the frequency of PrEP use required to achieve those
concentrations.
RESULTS
Intracellular TFV-DP, the active form of tenofovir, was analyzed in
PBMCs arising from two separate studies: the iPrEx trial and the
STRAND study. Data from these separate studies were combined to
understand the relationship between TFV-DP concentration and PrEP
efficacy in men who have sex with men. TFV-DP concentrations in
PBMCs from the iPrEx trial were used to estimate drug concentrations
associated with decreased HIV acquisition. TFV-DP concentrations in
PBMCs from the STRAND study were used to establish expected con-
centrations from two, four, or seven doses per week of directly observed
1University of ColoradoDenver, Aurora, CO80045, USA. 2University of California, San Francisco,
San Francisco, CA 94143, USA. 3HIV Research Section, San Francisco Department of Public
Health, San Francisco, CA 94102, USA. 4Investigaciones Medicas en Salud, Lima 14, Peru.
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CEP 21040-900, Brazil. 10Brown University, Providence, RI 02912, USA. 11Fenway Institute,
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em Imunologia, Cerqueira Cesar, São Paulo, SP CEP 05403-900, Brazil.
*To whom correspondence should be addressed. E-mail: robert.grant@ucsf.edu
R E S EARCH ART I C L E
www.ScienceTranslationalMedicine.org 12 September 2012 Vol 4 Issue 151 151ra125 1
 o
n 
Se
pt
em
be
r 2
6,
 2
01
2
stm
.sc
ien
ce
m
ag
.o
rg
Do
wn
loa
de
d 
fro
m
 
TDF therapy. PrEP efficacy was then quantified for two, four, and
seven doses per week by analyzing TFV-DP concentrations from the
STRAND trial with the iPrEx HIV risk reductionmodel. PBMC collec-
tion, processing, and storage for the iPrEx and STRAND trials used
identical laboratory protocols, and drug concentration testing was per-
formed in the same laboratory using identical laboratory methods.
Predicted TFV-DP concentrations in the STRAND trial
STRAND was an open-label crossover study of oral TDF in 24 HIV-
negative adults (FTC was not included), each of whom received two,
four, and seven doses per week for 6 weeks. Dosing was directly ob-
served Monday to Friday, including all of the two and four doses per
week (Tuesday/Wednesday and Monday/Tuesday/Thursday/Friday,
respectively), and participants provided confirmation of the date
and time of doses taken on Saturday and Sunday by text message or
telephone contact on the day of use. TFV-DP concentrations in PBMCs
were measured at the end of the 6 weeks of each dosing regimen. The
median [interquartile range (IQR)] values in STRANDwere 11 fmol/106
PBMCs (6 to 13) for two doses per week, 32 fmol/106 PBMCs (25 to 39)
for four doses per week, and 42 fmol/106 PBMCs (31 to 47) for seven
doses per week (left portion of Fig. 1). The median (IQR) times from
the last dose to PBMC collection were 24 (20 to 141) hours, 25 (22 to
62) hours, and 24 (21 to 25) hours, respectively. TFV-DP concentra-
tions were quantifiable in all STRAND participants at all visits.
Drug detection at the visit with first evidence of HIV
infection in the iPrEx trial
The iPrEx study was used to identify drug concentrations associated
with different levels of protection from HIV-1 acquisition. Plasma
and/or PBMCs were tested for FTC-TDF concentrations in all 48
seroconverters at the visit when HIV-1 infection was first detected,
using either plasma viral RNA, serum antibodies, or both. Themedian
time between the last HIV-negative test and the first evidence of HIV
was 33 days (IQR, 28 to 48 days). EachHIV-infected casewasmatched
to three seronegative controls in the FTC-TDF arm by study site and
duration of the study. One of the three controls was selected on the
basis of having reported high-risk sexual practices, to ensure compa-
rable HIV-1 exposure with cases, and the other two were selected ran-
domly. The cases and controls were comparable with respect to HIV
risk factors, level of schooling, and alcohol use (Table 1). Both plasma
and PBMCs were tested in 42 of 48 (88%) of cases at the visit when
HIV-1 infection was first detected and in 144 of 144 (100%) of
controls at the matched time point of the study. Plasma and/or
PBMCs were also tested from other longitudinal study visits in the
Fig. 1. TFV-DP concentrations in the STRAND and iPrEx trials. The values
observed in the STRAND study are shownon the left for two doses perweek
(open circles), four doses per week (light gray circles), and seven doses per
week (dark gray circles). iPrEx values on the right included those from the
visit with first evidence of HIV infection in cases (red triangles) and the
matched study visit in HIV-negative controls (black triangles). The blue bars
represent the medians. The numbers of participants tested (the proportion
of PBMCs tested with detectable TFV-DP concentrations), the median con-
centrations among values in the detectable range, and the IQRs are listed
below the x axis. BLQ, below the limit of quantification of the assay.
Table 1. Demographic and HIV risk characteristics at baseline among analysis groups in the iPrEx study.
Cases (n = 48) Controls (n = 144) P
Baseline
Age in years, mean (SD) 24 (6) 27 (8) 0.01
Calculated CrCl ml/min, mean (SD) 125 (23) 121 (22) 0.30
Male partners in past 6 months, mean (SD) 12 (32) 13 (46) 0.78
Secondary school, n (%) 31 (66) 109 (76) 0.19
Alcohol use (≥5 drinks per day on days when drinking), n (%) 24 (52) 74 (54) 0.87
Unprotected receptive anal intercourse, n (%) 34 (71) 109 (76) 0.57
History of sexually transmitted infection in past 6 months, n (%) 15 (31) 52 (36) 0.60
Herpes seropositive, n (%) 24 (50) 69 (48) 0.87
At time of HIV detection in cases
Weeks on study, mean (SD) 63 (35) 65 (36) 0.73
Unprotected receptive anal Intercourse, n (%) 19 (40) 74 (51) 0.18
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cases and controls. Drug detection was defined as any quantifiable
moiety among plasma TFV, FTC, and intracellular TFV-DP and
FTC-TP. Drug detection in plasma and PBMCs in the iPrEx trial
was concordant in >95% of all pairwise comparisons, indicating that
plasma and PBMCanalysis yielded similar estimates of the proportion
of groups having detectable drug.
Any drug moiety was detected 5.5-fold less frequently (8% versus
44%; P < 0.001) in HIV-positive cases at the visit when HIV infection
was first detected compared with the matched time point in HIV-
negative controls (Fig. 2). Lower drug detection among cases versus
controls (11% versus 51%; P < 0.001) was also observed within the
90 days before the HIV infection visit or matched time point in con-
trols. At time points more than 90 days before HIV was first detected,
the proportion of cases and controls with any detectable drug was
comparable (36% versus 41%; P = 0.77), indicating that HIV infection
occurred during periods of low drug exposure in the active arm of the
iPrEx trial. These drug detection rates suggest that a substantial frac-
tion of iPrEx participants were dosing with fewer than two doses per
week, given the 100% TFV-DP detection rate for two doses per week
in the STRAND trial (right portion of Fig. 1).
TFV-DP concentrations and risk of HIV acquisition
In the iPrEx seronegative controls having quantifiable TFV-DP concen-
trations (36% of the total), the median concentration was 16 fmol/106
PBMCs (IQR, 9 to 27), which was between the median concentrations
observed for two and four doses per week in the STRAND trial (Fig. 1).
Only 18% of seronegative controls had TFV-DP concentrations in the
range associated with daily dosing in the STRAND study. This suggests
that TFV-DP concentrations below those associated with daily dosing
were exerting antiviral effects to give the 44%overall efficacy in the group
randomized to FTC/TDF versus placebo. Only three HIV-infected cases
had detectable TFV-DP concentrations at the time HIV was first de-
tected. These concentrationswere in the range of those associated with
two doses per week in the STRAND trial and nonewere in the range of
daily dosing.
The TFV-DP concentration in PBMCs associated with HIV-1 ac-
quisition was estimated using a Cox proportional hazardsmodel that
assessed the risk of HIV infection in the iPrEx trial as a function of
TFV-DP (or FTC-TP) concentrations in active-arm participants. Ex-
ponential regression was also used in a second analysis. Multiple impu-
tation (8, 9) was used to construct a data set with drug concentrations
at each visit when an HIV-1 test was performed. If a drug concentra-
tion was not available, imputation was used using information about
the participant [age, site, time on study, numbers of partners, creatinine
clearance, alcohol use, secondary education, infection with herpes sim-
plex virus (HSV), sexually transmitted disease, pharmacy drug dis-
pensation records, and unprotected receptive anal intercourse (URAI)
at baseline and follow-up] to estimate the missing concentration. This
approach allowed HIV-1 risk to be estimated for the entire cohort and
to estimate how drug exposure as a time-dependent variable was asso-
ciated with HIV risk compared with the placebo arm. Drug concentra-
tions below the limit of quantitation (BLQ) were set to 0 fmol/106
PBMCs.
The relationship between drug concentrations and HIV infection
riskwas significant for bothTFV-DP (P=0.016) andFTC-TP (P=0.004)
among those assigned to receive oral FTC/TDF. Compared with HIV
incidence for the placebo arm, the TFV-DP concentrations associated
with 50, 90, and 99% reduced HIV-1 acquisition were 3 [95% confi-
dence interval (CI), <1 to 7], 16 (95% CI, 3 to 28), and 33 (6 to 60)
fmol/106 PBMCs, respectively. For FTC-TP, the corresponding values
were 0.82 (0.1 to 1.6), 3.7 (1.2 to 6.1), and 7.7 (2.6 to 12.9) pmol/106
PBMCs, respectively. However, neither TFV-DP nor FTC-TP concen-
trations were independent of the other in a model that included both;
therefore, further analyses focused on TFV-DP concentrations so that
TFV-DP concentrations from the STRAND trial could be used.
Dosing and risk of HIV acquisition
The exponential regression shown in Fig. 3 demonstrated that the risk
of HIV infection was comparable among participants in the active arm
with undetectable TFV-DP concentrations compared to the placebo
arm (relative hazard, 0.78; 95% CI, 0.49 to 1.06; P = 0.19). Similar to
theCox analysis above, a TFV-DPconcentration of 16 fmol/106 PBMCs
was associated with 90% HIV risk reduction (EC90) relative to placebo.
For perspective, the concentrations from the STRAND study are shown
in colored panels in Fig. 3. The EC90 (16 fmol/10
6 PBMCs) was 38% of
the median TFV-DP concentration observed in those taking seven
doses per week in STRAND (42 fmol/106 PBMCs).
Sensitivity analyses were conducted to evaluate the robustness of
the estimated EC90 TFV-DP concentration in PBMCs. An analysis that
adjusted forURAI (themain risk factor forHIV acquisition in this pop-
ulation) and other factors also used for multiple imputation, yielded
an estimate of 15 (95%CI, 3 to 27) fmol/106 PBMCs.Allowing drug con-
centrations below the limit of quantitation to vary uniformly between
0 and 5 yielded an estimate of 20 (95% CI, 7 to 33) fmol/106 PBMCs.
Using the averaged drug concentrations from the visit closest to HIV
infection with values in the previous 90 days yielded an estimate of
23 (5 to 41) fmol/106 PBMCs. An analysis that brought drug detec-
tion at subsequent seroconversion time points to the time of the first
detection of HIV-1 RNA yielded an estimate of 19 (95% CI, 4 to 33)
fmol/106 PBMCs. Adjustment of TFV-DP concentration (from 4.19
to 13.4 fmol/106 PBMCs) in one person whose blood specimen was
D
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Fig. 2. Longitudinal drug detection relative to the timeof first HIV-1 detec-
tion in the iPrEx trial. Shown are the percent of case and control timepoints
with any drug detection in plasma or PBMCs, including TFV, FTC, TFV-DP, or
FTC-TP, at the timeof first laboratory evidence ofHIV in cases or thematched
time point in controls (dashed vertical line), and at pre- and post-HIV infec-
tion time points. The pre- and post-HIV infection time points were divided
into those within 3 months (90 days) before or after HIV infection, and those
within 6-month intervals distal to these time points. The number of time
points with either plasma or PBMCs available for testing is listed for each
time period. *P < 0.05, cases versus controls.
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available 7 days after stopping oral FTC/TDF at seroconversion yielded
an estimate of 20 (95%CI, 4 to 36) fmol/106 PBMCs. Estimating a TFV-
DP concentration associated with a 90% HIV risk reduction in cases
versus controls was also possible using conditional logistic regression
without multiple imputation. This analysis yielded a similar estimate
for the EC90 for PBMCs of 16 fmol/10
6 PBMCs (95%CI, 8 to 44). All es-
timates were comparable with the initial EC90 estimate of 16 fmol/10
6
PBMCs and well within the range of concentrations achieved with four
to seven tablets per week in the STRAND trial.
The fraction of case and control time points that exceeded the EC90
over time is shown in Fig. 4. At the visit when HIV was first detected,
no cases (0 of 42) had TFV-DP concentrations≥16 fmol/106 PBMCs,
compared with 18% (26 of 144) of seronegative controls at thematched
time point (P < 0.001; Fig. 4). The proportion of iPrEx participant time
points with TFV-DP concentrations at or above the EC90 decreased
among cases (P = 0.02) and controls (P < 0.001) over time. Reported
risk behavior associated with exposure to HIV-1 also decreased over
time among iPrEx participants (1).
TFV-DP concentrations arising from two, four, and seven directly
observed doses perweek in the STRANDstudywere analyzedwith the
exponential regression model from the iPrEx trial described above.
The estimated PrEP efficacy was 76% (95% CI, 56 to 96%) for two
doses per week, 96% (95% CI, 90 to >99%) for four doses per week,
and 99% (95% CI, 96 to >99%) for seven doses per week. The
proportions of people who attained the TFV-DP EC90 were 14% for
two tablets per week, 90% for four tablets per week, and 100% for sev-
en tablets per week.
DISCUSSION
This study identified that a TFV-DP concentration of 16 fmol/106
PBMCs was associated with 90% reduced risk of HIV-1 acquisition
in the iPrEx trial. The number of tablets per week to consistently reach
that concentration was estimated to be four or more using information
from a directly observed dosing study, STRAND. These findings to-
gether suggest that oral FTC-TDF PrEP is a robust intervention for
men having sex with men, with a relatively wide prophylactic window.
Drug exposure in HIV-infected cases in the iPrEx trial was crit-
ically low at the time of first laboratory evidence of HIV infection, pro-
viding a likely explanation for HIV acquisition in these participants.
Other evidence indicated negligible drug exposure near the time of
HIV infection in cases: Plasma HIV-1 RNA levels were comparable
in the placebo and active arms, and there was no evidence of TDF or
FTC resistance among emergent infections in the active arm (1). Drug
detection in controls was higher than in cases butwas not commensurate
with daily dosing in the majority. Only 44% of controls had any detect-
able drug moiety at the matching time point of the case. Only 18% of
seronegative controls had TFV-DP concentrations above 16 fmol/106
PBMCs, a level achieved by 90% of STRAND trial participants taking
four or more doses per week, and a level associated with a 90% HIV
infection risk reduction.
Theminimumprotective drug concentrations in the blood and the
number of tablets per week required to achieve those concentrations
may differ depending on the route and frequency of exposure to HIV
(10). For men who have sex with men, the tissue of greatest relevance
to the acquisition of HIV-1 infection is the rectal mucosa. Oral dosing
has been shown to deliver 20- to 100-fold higher TFV-DP in rectal tis-
sue compared with blood or vaginal/cervical tissue (11, 12). TFV-DP
delivery to penile tissue, relevant for male insertive exposures, has not
been determined to our knowledge. The high delivery of TFV-DP to
rectal mucosa suggests that pharmacological findings relevant for
men who have sex with men, such as in this study, may not directly
extrapolate to parenteral, vaginal, or penile exposures.
This study has demonstrated that the EC90 in PBMCs (16 fmol/10
6
PBMCs) was 38% of the median for daily dosing in the STRAND trial
Fig. 4. Percent of case and control time points with TFV-DP concentrations
≥16 fmol/106 PBMCs (estimated EC90) in the iPrEx trial. Black circles repre-
sent HIV-negative controls, and red circles represent HIV-infected cases.
The x axis represents time relative to the visit with first evidence of HIV in-
fection in the case and thematching timepoint in controls. Pre- andpost-HIV
infection time points were divided into those within 3 months (90 days)
before or after HIV infection, and those within 6-month intervals distal
to these time points. The number of time points with PBMCs tested for
TFV-DP concentrations is listed for each time period. *P < 0.05, cases versus
controls.
Fig. 3. Estimated HIV incidence from exponential regression model of
TFV-DP concentrations (fmol/106 PBMCs) in the iPrEx trial. The HIV infection
rate in the placebo arm is shown as a horizontal black line at 3.9 infections
per 100 person-years (P-Y), with the relative rate in the FTC-TDF arm (blue
solid line) according to TFV-DP concentrations (x axis). Dashed lines repre-
sent the 95%CIs. The IQRs of TFV-DP concentrations associatedwith direct-
ly observed dosing in the STRAND study are provided as colored panels
overlying the curves for HIV incidence versus TFV-DP concentration in
the iPrEx trial. BLQ, below the limit of quantification of the assay.
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(42 fmol/106 PBMCs).With this information, a rectal mononuclear cell
EC90 can be estimated. The rectal mononuclear cell concentration ob-
served with daily oral dosing was reported to be 1846 fmol/106 cells
(95% CI, 931 to 3659) (11). Assuming that the kinetics of TFV-DP in
rectal mononuclear cells are similar to those in PBMCs, the EC90 in rec-
tal mononuclear cells would be 38% of this value, or about 700 fmol/106
rectal cells (95% CI, 350 to 1400). This estimate makes several assump-
tions that require further validation but nevertheless provides a starting
point for a target cell concentration in tissue to translate into animal or
ex vivo systems for validation (13, 14). The threshold identified here
is analogous to the TFV concentration threshold of 1000 ng/ml in vagi-
nal fluid identified as protective in another PrEP trial, the CAPRISA 004
study, and in ex vivo assays (5, 14).
Drug concentrations were measured as close to HIV infection as
possible (at the time HIV infection was first discovered and within
90 days of this time point). Through use of multiple imputations, drug
concentrations were assigned to all active-arm participants at the time
of HIV infection in placebo cases. However, the model could not ac-
count for variations in dosing patterns and relationship to timing of
HIV exposure and transmission risk.
Confounding is also possible in this analysis, because there may be
factors that link higher adherence with lower exposure to HIV. The
finding that HIV acquisition among active-arm participants with un-
detectable drug concentrations was not higher than the placebo rate
argues against confounding (Fig. 3). In addition, the statistical analysis
adjusted for several markers of HIV incidence, including numbers of
sexual partners, unprotected anal intercourse, sexually transmitted dis-
eases, age, level of schooling, and substance use.
Viable cryopreserved PBMCs were available for drug analysis,
whereas freshly processed and lysed PBMCs are traditionally used for
cell pharmacology studies (15). Measurements of TFV-DP concentra-
tions in PBMCs from the STRAND trial were amedian of 48% (IQR, 38
to 67%) that of freshly lysed PBMCs also collected in that study. Process-
ing PBMCs also introduced additional variability in TFV-DP/FTC-TP
measurements. Despite this added variation, drug concentrations in
blood were found to be strongly associated with reduced HIV risk in
the active arm compared with placebo in the iPrEx trial. This finding
suggests that drug concentration monitoring could inform HIV acqui-
sition risk in persons taking FTC/TDF for PrEP.Other specimens, such
as hair or dried blood spots, may afford more convenient long-term
measures of drug exposure thatwill be particularly useful if they can be
correlated with protective drug concentrations in PBMCs (16, 17).
This study identified a relationship between systemic drug expo-
sure and reduction ofHIVacquisition risk in one important population.
Protective TFV-DP concentrations were readily achieved with four or
more doses per week. This study focused on TFV-DP because inde-
pendent relationships for FTC-TP could not be identified in the iPrEx
study, and the STRAND trial did not include FTC-TP; thus, expected
concentrations for nondaily dosing are not known. FTC coadministra-
tion is not expected to affect intracellular concentrations of TFV-DP in
PBMCs (18). The TFV-DPEC90 in the iPrEx trial was calculated with
the presence of FTC-TP, indicating that reaching these protective
TFV-DP concentrations with FTC-TDF dosing is relevant for PrEP ef-
ficacy in men who have sex with men. Nevertheless, future studies
should aspire to evaluate the contribution of FTC-TP, as well as TFV-
DP, to PrEP efficacy.
Alternative dosing regimens, such as pre- and post-intercourse dos-
ing, warrant controlled clinical trials to evaluate the acceptability, behav-
ioral feasibility, and pharmacokinetics of nondaily regimens. The 95%
CI for the estimate of the TFV-DP EC90 was 3 to 28 fmol/10
6 PBMCs.
The lower bound (3 fmol/106 PBMCs)would be achievable after a single
dose (19), and 28 fmol/106 PBMCs was just below the median achieved
with four doses per week in STRAND.Whereas animal studies indicate
that both pre- and post-exposure dosing are important (20), more
information is needed to define the timing and duration of drug expo-
sure that is required to prevent infection. Dose optimization in the ab-
sence of a surrogate marker of protection would require prohibitively
large trials, so better definition of pharmacological parameters asso-
ciated with differing dosing strategies (for example, dose and dosing in-
terval) and protection will be essential to move the PrEP field forward.
Ultimately, recommendations for daily PrEP use may be more robust
because daily regimens encourage a routine and afford drug concentra-
tions that are expected to persist in the protective range even if some
doses are missed. The low fraction of iPrEx participants with TFV-
DP concentrations in the range of daily dosing suggests that demonstra-
tion projects should optimize ways to promote daily dosing.
In conclusion, this study identified a target TFV-DP concentration for
protecting against HIV-1 acquisition in men who have sex with men.
This threshold should enable further studies to be conducted in men
who have sex with men to evaluate new ways of promoting the consist-
ent use of PrEP, thus maximizing the probability of PrEP efficacy.
MATERIALS AND METHODS
iPrEx trial
The design, conduct, and outcomes of the iPrEx trial have been pub-
lished previously (1). Briefly, the iPrEx initiative was a randomized,
double-blinded, controlled trial of daily FTC-TDF versus placebo in
HIV-negative men and transgender women 18 years or older who have
sexwithmen,meeting behavioral criteria that put themat risk for sexual
acquisition of HIV. Two thousand four hundred ninety-nine partici-
pants were randomized and followed monthly through a median of
87 weeks of therapy (IQR, 61 to 125). In the final analysis, 83 infections
were observed in the placebo arm versus 48 infections in the FTC-TDF
arm (efficacy, 42%; 95% CI, 18 to 60%) (21).
Plasma specimens were stored every 12 weeks, and viable cryopre-
served PBMC specimens were stored every 24 weeks and at the time of
study discontinuation or seroconversion. Each participant from the
active arm who contracted HIV during the study was included in this
pharmacology substudy (cases). For each visit week when HIV was de-
tected in cases, samples were selected from three HIV-negative controls
from the active armat the same site: two randomly andone fromamong
those reporting URAI in a recall period before the specimen collection.
The latter control was chosen to enrich the control sample for people
exposed to HIV, to better match the HIV-infected cases. Specimens
were tested from the time of first evidence of HIV infection in the cases,
the nearest visit week in controls, as well as longitudinally at other avail-
able time points during the treatment period.
STRAND study
The STRAND study was an open-label, randomized, six-sequence,
three-period, single-site, crossover trial in 24 HIV-negative adults
(12 men and 12 women) that tested the effects of three different oral
TDF dosing regimens on TFV concentrations in hair, plasma, and
PBMCs. The six sequences were different orders of the three dosing
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strategies: seven doses per week, four doses per week, and two doses
per week. The two doses per week were taken on Tuesday andWednes-
day, and the four doses per week on Monday, Tuesday, Thursday, and
Friday. Each dosing period lasted 6 weeks. All doses scheduledMonday
to Friday were directly observed by study staff, and the doses on the
weekend were confirmed by telephone or text message. Stored viably
cryopreserved PBMCs (using the same method as in iPrEx) were
collected at the end of each 6-week dosing period. Freshly processed/
lysed PBMCs were available from a subset of participants. The study
was funded by the U.S. National Institutes of Health and was approved
by the University of California, San Francisco, Committee on Human
Research.
Analytical pharmacology
A liquid chromatography–tandem mass spectrometry (LC-MS/MS)
assay was validated for the determination of TFV and FTC in human
plasma (22). The method includes protein precipitation and stable
isotopic internal standards. The linearity of the concentration curves
was in the range of 10 to 1500 ng/ml for both analytes (250 ml of
plasma extracted). The lower limit of quantification was 10 ng/ml
for both analytes.
The viable PBMC processing procedure involved a quick thaw in a
37°C water bath and mixing by inversion (1 min). Cells were imme-
diately transferred to a 15-ml centrifuge tube that already contained
10 ml of prewarmed (37°C) phosphate-buffered saline followed by
gentle mixing by inversion. Cells were then pelleted and the super-
natant was discarded. If red blood cell (RBC) contamination was vis-
ible, the cells were treated with an RBC lysing buffer. Cells were then
counted with an automated hemocytometer. Viability and total cell
count were recorded; cells were kept on crushed ice through the pro-
cess. Cells were washed and lysed. Median (IQR) viability at the time
HIVwas discovered was 66% (56 to 76%) overall, 71% (56 to 79%) in
cases, and 64% (56 to 73%) in controls.
A validated LC-MS/MS assay was used for the determination of
TFV-DP and FTC-TP from lysed intracellular matrix (15). The meth-
od used a strong anion exchange isolation of mono-, di-, and triphos-
phates from intracellular matrix. The triphosphate fraction was then
dephosphorylated to the parent moiety, yielding a molar equivalent to
the original nucleotide analog intracellular concentration. The analyt-
ical portion included desalting/concentration by solid-phase extrac-
tion and detection by LC-MS/MS. The quantifiable linear range for
TFV-DP was 2.5 to 2000 fmol per sample and that for FTC was 0.1
to 200 pmol per sample. Stable labeled isotopic internal standards fa-
cilitated accuracy and precision in various cell matrices (15). Twomil-
lion total cells were typically extracted, constituting the “sample,” and
results were corrected for cell viability and normalized to femtomole
or picomole per million viable cells.
Stored viable PBMC samples such as in this study have been used
for the measurement of intracellular TFV-DP in previous studies [see
Appendix in (1)]. These studies demonstrated that values in viably cryo-
preserved PBMCs (median, about 40 fmol/106 viable PBMCs) were
lower than those measured in pharmacology studies among HIV-
infected subjects, where PBMC samples were processed and lysed im-
mediately (median, about 90 fmol/106 PBMCs) (23, 24).
To evaluate viable cells in more detail, an internal study called
iOptimum enrolled 10 HIV-infected participants for a single blood
draw to assess the TFV-DP and FTC-TP in viable cryopreserved cells.
Self-reported adherence in the previous 30 days was 63 to 100%, and
viral loads were largely suppressed (range, <40 to 240 copies/ml), sug-
gesting good adherence to treatment. Aliquots of viable cells were stored
in liquid nitrogen for 4, 12, and 24 weeks. Freshly lysed cells were also
collected. Both TFV-DP and FTC-TP were quantifiable in all viable
PBMCsamples and above the lower limit of quantitation by several fold.
The median (IQR) ratio of viable PBMCs/PBMCs at weeks 4 and 12 in
liquid nitrogen storage was 0.3 (0.22 to 0.38). The median (IQR) value
for 24weeks in liquid nitrogenwas 0.56 (0.38 to 0.83), whichwas similar
to STRAND, 0.48 (0.38 to 0.67). Median (IQR) time in liquid nitrogen
for iPrEx and STRAND samples was 70 (46 to 108) weeks and 57 (52 to
65) weeks, respectively. We have observed no loss in viable cell con-
centrations for storage times in liquid nitrogen through 119 weeks
(2.3 years) (1).
Statistical methods
All analyses were performed with Stata 12.1 (25).
Model for the effect of intracellular drug concentration
This analysis fits a (stratified by site) Cox proportional hazards
model to the entire cohort with the following model:
hkðt;ZðtÞ, rxÞ ¼ h0kðtÞexpðb1rxþ b2ZðtÞÞ ð1Þ
hk(t) is the hazard of HIV infection at the kth site and rx = 1 if the
participant is assigned to FTC/TDF and 0 if the participant is assigned
to placebo. The variable Z(t) is a time-dependent covariate for a quan-
titative drug concentration (for example, TFV-DP), where Z(t) is set to
be a drug concentration of 0 if the participant is on the placebo group.
We examined quadratic and logarithmic transformations of the con-
centration Z(t), but neither improved the fit.
The primary analyses have used models stratified by clinic site to
avoid confounding the association between drug concentrations and
HIV acquisition. Stratification was incorporated into the design of the
nested case-control study by matching controls by study site. Stratifica-
tion can be highly efficient relative to an unstratified model even if
confounding by site is weak (26).
Model 1 uses the placebo group as the baseline hazard function
permitting comparison of the hazard of HIV acquisition at a given drug
concentration to the placebo group. For instance, the concentration
Z(t), which is associated with a d% reduction in risk relative to placebo,
is as follows:
flogð1 − d=100Þ − b1g=b2
The concentration associated with a d% reduction in risk rela-
tive to a 0/BLQ concentration on the FTC/TDF arm is as follows:
logð1 − d=100Þ=b2
Here, b1 is the log hazard ratio of a 0/BLQ level on the FTC/TDF arm
(relative to placebo), b2 quantifies the change in risk with the concen-
trations of drug, and h0k(t) is the baseline hazard ofHIV seroconversion
on the placebo arm.
We also fit
aðt; Z, rxÞ ¼ a expfa1rxþ a2ZðtÞg ð2Þ
where this exponential model is parameterized to yield the annualized
incidence of HIV. The fit of this model to the data yielded similar
results to the fit of model 1 and was used as the basis of the annualized
HIV incidence graphed in Fig. 3.
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Note that models 1 and 2 require a complete set of drug concentra-
tions for participants in the active arm. We must confront two types of
missing data. First, only a randomly selected subset of time points had
drug concentrations tested. Second, intracellular drug (TFV-DP, FTC-
TP) was only tested every 6 months and at the time of HIV sero-
conversion. Hence, even if a control has drug concentration tested,
the information is sparse and may not correspond to an ideal time
match to their HIV case.
We used two strategies for fitting model 1 with missing data in the
drug concentrations: multiple imputation and conditional logistic re-
gression. Conditional logistic regression functions only as a sensitivity
analysis because it is unable to use the placebo group as a reference and
does not handle the uncertainty in drug concentrations in the controls
because of the long periods of time betweenmeasurements of drug con-
centrations.
Multiple imputation
The concentration of drug for theHIV-infected cases at the time ofHIV
infection was taken as the intracellular concentration observed at the
first laboratory evidence of HIV infection. Six participants lacked an in-
tracellular specimen at the first laboratory evidence of HIV infection—
all had a plasma specimen at the first evidence of infection and all were
BLQ for TFV and FTC. In the case-control study of 355 plasma speci-
mens that are BLQ for TFV and FTC, 96% were BLQ for TFV-DP and
95%were BLQ for FTC-TP. Hence, the TFV-DP and FTC-TP for these
six seroconverters were set as BLQ.
For controls, we attempted to infer the drug concentration at the
identical day of follow-up as seroconverters from the same site.We used
the closest intracellular drug concentration within 45 days as the drug
concentration if one was available and considered that as a measured
drug concentration. If there was no tested drug concentration within
45 days, then drug concentrations were imputed. Varying the 45-day
window had little effect on the results.
If the visit had plasma but not intracellular concentrations
(PBMCs), we used whether the plasma had detectable or not in our
imputation model. We performed multiple imputations (9) of TFV-
DP, FTC-TP, and any detection of drug in plasma or PBMCs using
medication possession ratio (defined as the number of tablets dis-
pensed at the previous visit divided by days since the last visit at which
medication was dispensed), study week, URAI at baseline, URAI at
follow-up (most recent report on or after the time point), baseline
HSV status, number of male sexual partners at screening, participant
report of a sexually transmitted infection in the 6 months before en-
rollment, secondary education, age at enrollment (in years), and base-
line (estimated) creatinine clearance (by Cockcroft-Gault equation).
Plasma and PBMC concentrations have monotone missingness; hence,
chained imputation was used to create joint imputations. The impu-
tation model for detection of drug in plasma was based on logistic
regression, and imputations for TFV-DP and FTC-TP were based
on predictive means matching (8). Predictive means matching used
a regressionmodel to identify observed values in the data, which form
the most plausible value for the imputations, yielding nonparametric
imputations that must follow the observed distribution of the drug
concentrations. This method seamlessly imputed concentrations of
TFV-DP and FTC-TP that were BLQ. This permitted us to form im-
putations in a first stage of analysis and to vary the strategy for quan-
tifying BLQ values in a second stage. We performed 20 imputations
per observation.
Conditional logistic regression
Analyses with conditional logistic regression mimic a (stratified)
Cox proportional hazards model among participants on the active
arm of the form
hkðt; ZÞ ¼ h0kðtÞexpfb3ZðtÞg ð3Þ
where k is the clinic site and Z(t) is a time-dependent covariate for drug
concentration. Prentice and Breslow demonstrated that by measuring
covariates in cases and a sample of (timematched) controls, it was pos-
sible to fit model 3 using a conditional logistic regression model (27).
Hence, the coefficient in the conditional logistic regression is a valid
estimator of the log hazard ratio b3, which is the risk reduction com-
pared to a drug concentration of 0 on the active arm. As a sensitivity
analysis, we compared the results of our estimated protective concen-
trations by calculating the intracellular drug concentrations associated
with a d% reduction in risk relative to a 0/BLQ concentration on the
FTC/TDF arm as follows:
logð1 − d=100Þ=b3
Inferred protection
On the basis of estimates for model 1 fit using multiple imputation, we
estimated the protective effect of dosing regimens used in STRAND.For
this, we combined the parameter estimates from model 1 with the ob-
servedTFV-DP from the two, four, and seven tablets per week regimens
in STRAND. The estimated relative risk reduction was approximated
by the following equation:
100 1 − n−1D ∑
nD
i¼1
expfb
ˇ
1 þ b
ˇ
2ZiDg
 !
where (Z1D, …, ZnDD) were the nD observed TFV-DP concentrations
for D tablet per week regimen, and the parameter estimates were taken
from fitting model 1 using multiple imputation with associated 0.95
level Wald-based CIs.
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